Sareum Holdings PLC
03 December 2004
For Immediate Release 3 December 2004
SAREUM HOLDINGS PLC
("Sareum" or the "Company")
Ordinary Shares of 0.025 pence
Sareum Holdings plc (AIM: SAR), the structure-based drug discovery and services
business, was notified on 3rd December, 2004, that Billam AG purchased on 3rd
December a total of 5,700,000 Ordinary Shares and now holds, together with its
directors Peter Hoskins and Jemima Thorpe, 18,050,000 Ordinary Shares
representing 5.2 per cent. of the issued share capital of the Company.
For further information contact:
Sareum Ltd +44 (0) 1223 497 700
Tim Mitchell, Chief Executive Officer
Buchanan Communications +44 (0) 207 466 5000
Mark Court, Mary-Jane Johnson
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.